Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
268 Treffer:
31.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
32.
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute M
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-03
33.
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-03
34.
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment.
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-03
35.
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Posi
NCT Heidelberg » Für Ärzte » Studien » Kopf-/Hals Tumoren
Datum: 2026-04-03
36.
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-03
37.
A prospective, observational, multicenter clinical performance study to evaluate IOpener®-melanoma test for predicting response to combination or mono immunotherapy in stage III or IV cutaneous melanoma patients
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-03
38.
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-03
39.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Myelodysplastisches Syndrom (MDS)
Datum: 2026-04-03
40.
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic L
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-03